Investor Highlights

Pharmaxis Completes Treatment Phase in Pivotol Bronchitol Cystic Fibrosis Clinical Trial for US Market

Pharmaceutical research company Pharmaxis (ASX: PXS) today announced that the last of 423 patients has concluded treatment in its international clinical trial evaluating Bronchitol® (mannitol) for cystic fibrosis (CF). The topline results of the trial are expected to be reported in the second quarter of this year.

The Phase 3 trial known as DPM-CF-303 has been conducted in accordance with the requirements of the US Food and Drug Administration (FDA) to gain marketing approval for Bronchitol to treat adult CF patients in the United States. Subject to a positive trial outcome, a response will be submitted to the FDA and a decision on approval can be expected in the second half of 2018.

Read full ASX announcement – pdf

Half Year Report - 31 December 2016

Pharmaxis Ltd financial and directors' reports for the six months ended 31 December 2016

Read full ASX announcement – pdf

Shareholder Update - December 2016

Shareholder update for the quarter ending 31 December 2016

Read quarterly update - pdf

2016 Annual Report

2016 Statutory Annual Report

Read report – pdf